Condition: Cardiovascualr Disease · Lipids · Inflammation · Sponsor: Mario Negri Institute for Pharmacological Research
Hyperlipidemia is the main driver of atherosclerotic cardiovascular disease (ASCVD), both through direct effects and as trigger of the chronic inflammation behind a cardiovascular health-to-disease transition. While lipid-lowering is an effective way to reduce the ASCVD risk, the residual risk remains high. In addition, a substantial proportion of ASCVD events occur in the absence of overt hyperlipidemia. Several lines of evidence ranging from experimental models to population studies and interventional clinical trials support chronic inflammation as the causal residual risk of CVD. The CVD risk-associated lipid classes contain fatty acids that can be liberated and metabolized into both inflammation-promoting as well as inflammation-resolving drivers, providing the rationale for focusing on this balance in the present project. Above all, the omega-3 fatty acid class can resolve inflammation but the potential impact is currently largely underestimated in CVD preventive recommendations. As cardiovascular preventive measures ease the burden placed on the individual, population, and on the health care system, it is critical to raise public awareness for chronic inflammation as a causative and modifiable cardiovascular risk factor and to provide tools for how to control and monitor it. As an alternative to marine sources, principally eicosapentaenoic acid (EPA) and less docosahexaenoic acid (DHA) can be endogenously produced from alpha-linolenic acid (ALA) found in plant oils. Sec…
This description comes directly from the study's public registry record.
Marianna Cerrato, phD · +39 023901414617 · marianna.cerrato@marionegri.it
Antonella Vasamì, High school diploma · +39 023901414450 · antonella.vasami@marionegri.it
Always discuss trial participation with your own doctor first.
| Dr. Antonella Todesca | Avellino, AV, Italy | Not Yet Recruiting |
| Dr. Tommaso Reginato | Arese, MI, Italy | Recruiting |
| Istituto di Ricerche Farmacologiche Mario Negri | Milan, MI, Italy | Recruiting |
| Dr. Giosafatte Zappia | Paderno Dugnano, MI, Italy | Not Yet Recruiting |
| Ospedale Madonna delle Grazie Matera | Matera, MT, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07331103